ReS9-S

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug NameReS9-S
Drug Alias NameAlpha synuclein modulators (reMYND NV)ReS9-S Compounds (reMYND)Parkinson's program (reMYND)Parkinson's program (reMYND/Roche)ReS9-S7
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSynuclein alpha inhibitors
TargetsSynuclein alpha
Therapy Area/IndicationsParkinson Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumSwitzerland
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesRemynd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesRoche Holding AgRemynd
Active IndicationsN/A
Inactive IndicationsParkinson Disease

Other Information

ATC CodeN/A
Related LinksN/A